疗效和安全性-话题@MedSci

#疗效和安全性#

431篇内容 | 2628人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1720946, encodeId=db701e2094672, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Blood：口服cedazuridine/地西他滨治疗MDS和CMML的药代动力学、疗效和安全性, objectType=article, longId=192727, objectId=297f192e2779, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297f192e2779, replyNumber=0, likeNumber=72, createdTime=2021-01-14, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297f192e2779, moduleTitle=Blood：口服cedazuridine/地西他滨治疗MDS和CMML的药代动力学、疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=297f192e2779)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720940, encodeId=126c1e2094090, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet oncol：R-CHOP联合甲氨蝶呤和鞘内化疗治疗新确诊的IVLBCL的疗效和安全性, objectType=article, longId=190230, objectId=fcd3190230c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcd3190230c9, replyNumber=0, likeNumber=56, createdTime=2020-10-09, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcd3190230c9, moduleTitle=Lancet oncol：R-CHOP联合甲氨蝶呤和鞘内化疗治疗新确诊的IVLBCL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcd3190230c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720958, encodeId=017f1e2095803, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Arthritis Rheumatol：卡那单抗对sJIA患者的疗效和安全性, objectType=article, longId=197950, objectId=c29919e95055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c29919e95055, replyNumber=0, likeNumber=82, createdTime=2021-06-04, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c29919e95055, moduleTitle=Arthritis Rheumatol：卡那单抗对sJIA患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c29919e95055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720917, encodeId=5bab1e20917d1, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Blood：Ivosidenib 单药治疗新确诊的AML的疗效和安全性, objectType=article, longId=185067, objectId=0f6418506ed8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f6418506ed8, replyNumber=0, likeNumber=60, createdTime=2020-05-03, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f6418506ed8, moduleTitle=Blood：Ivosidenib 单药治疗新确诊的AML的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f6418506ed8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720915, encodeId=182a1e20915e5, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Arthritis Rheumatol：乌司奴单抗治疗系统性红斑狼疮的1年疗效和安全性, objectType=article, longId=183725, objectId=a150183e2554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a150183e2554, replyNumber=0, likeNumber=60, createdTime=2020-07-07, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a150183e2554, moduleTitle=Arthritis Rheumatol：乌司奴单抗治疗系统性红斑狼疮的1年疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a150183e2554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720914, encodeId=91291e2091479, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Rheum Dis：两项使用ixekizumab治疗活动性放射学axSpA 3期临床试验的疗效和安全性（COAST-V和COAST-W）, objectType=article, longId=183366, objectId=0e97183366d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e97183366d9, replyNumber=0, likeNumber=89, createdTime=2020-08-14, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e97183366d9, moduleTitle=Ann Rheum Dis：两项使用ixekizumab治疗活动性放射学axSpA 3期临床试验的疗效和安全性（COAST-V和COAST-W）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e97183366d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720939, encodeId=5f651e209393b, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet oncol：维奈托克联合阿糖胞苷±伊达比星用于AML患儿的疗效和安全性, objectType=article, longId=190228, objectId=dcf9190228b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcf9190228b4, replyNumber=0, likeNumber=71, createdTime=2021-01-21, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcf9190228b4, moduleTitle=Lancet oncol：维奈托克联合阿糖胞苷±伊达比星用于AML患儿的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcf9190228b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720932, encodeId=92c61e20932f0, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Medicine ：舍曲林治疗早泄的疗效和安全性分析, objectType=article, longId=188899, objectId=85c718889980, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85c718889980, replyNumber=0, likeNumber=62, createdTime=2020-12-26, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85c718889980, moduleTitle=Medicine ：舍曲林治疗早泄的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85c718889980)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720950, encodeId=b3521e2095075, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Stroke：大血管闭塞的急性缺血性卒中患者再通疗法的疗效和安全性, objectType=article, longId=195254, objectId=0f46195254fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f46195254fd, replyNumber=0, likeNumber=52, createdTime=2020-06-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f46195254fd, moduleTitle=Stroke：大血管闭塞的急性缺血性卒中患者再通疗法的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f46195254fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720924, encodeId=34861e209243a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Blood：Avadomide(CC-122)单药治疗难治性/复发性DLBCL的疗效和安全性, objectType=article, longId=187353, objectId=19ef18e35330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19ef18e35330, replyNumber=0, likeNumber=65, createdTime=2020-02-26, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19ef18e35330, moduleTitle=Blood：Avadomide(CC-122)单药治疗难治性/复发性DLBCL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19ef18e35330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720960, encodeId=385e1e20960ae, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Diabetes Obes Metab：老年2型糖尿病患者埃格列净治疗的疗效和安全性, objectType=article, longId=198048, objectId=4f291980487e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f291980487e, replyNumber=0, likeNumber=56, createdTime=2021-02-04, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f291980487e, moduleTitle=Diabetes Obes Metab：老年2型糖尿病患者埃格列净治疗的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f291980487e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720925, encodeId=b1731e2092570, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=拜耳的Eylea在针对湿性年龄相关性黄斑变性的ALTAIR IV期研究中展现出疗效和安全性, objectType=article, longId=187857, objectId=d62e18e85710, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d62e18e85710, replyNumber=0, likeNumber=63, createdTime=2020-07-01, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d62e18e85710, moduleTitle=拜耳的Eylea在针对湿性年龄相关性黄斑变性的ALTAIR IV期研究中展现出疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d62e18e85710)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720941, encodeId=75391e2094164, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Neurology：Eptinezumab单抗治疗慢性偏头痛的疗效和安全性, objectType=article, longId=190816, objectId=2cd21908167c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cd21908167c, replyNumber=0, likeNumber=77, createdTime=2020-06-11, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cd21908167c, moduleTitle=Neurology：Eptinezumab单抗治疗慢性偏头痛的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cd21908167c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720947, encodeId=190b1e2094789, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Urol Int：他达拉非每日一次与按需使用对勃起功能障碍患者的疗效和安全性, objectType=article, longId=192984, objectId=d7821929846e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7821929846e, replyNumber=0, likeNumber=59, createdTime=2020-08-29, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7821929846e, moduleTitle=Urol Int：他达拉非每日一次与按需使用对勃起功能障碍患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7821929846e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720918, encodeId=6dc61e20918f8, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Gastroenterology：急诊和选择性结肠镜检查对急性下消化道出血的疗效和安全性分析, objectType=article, longId=185442, objectId=072a18544228, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=072a18544228, replyNumber=0, likeNumber=62, createdTime=2020-09-24, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=072a18544228, moduleTitle=Gastroenterology：急诊和选择性结肠镜检查对急性下消化道出血的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=072a18544228)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720948, encodeId=acef1e20948a3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Rheum Dis：苏金单抗对难治性白塞病黏膜和关节表型的长期疗效和安全性, objectType=article, longId=193763, objectId=6f30193e6349, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f30193e6349, replyNumber=0, likeNumber=80, createdTime=2021-04-03, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f30193e6349, moduleTitle=Ann Rheum Dis：苏金单抗对难治性白塞病黏膜和关节表型的长期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f30193e6349)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720919, encodeId=65d01e2091918, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Oncol：鲁索替尼治疗有无CSF3R突变的CNL或aCML患者的疗效和安全性, objectType=article, longId=185703, objectId=5b57185e0330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b57185e0330, replyNumber=0, likeNumber=70, createdTime=2020-03-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b57185e0330, moduleTitle=J Clin Oncol：鲁索替尼治疗有无CSF3R突变的CNL或aCML患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b57185e0330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720949, encodeId=ac141e20949ef, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Arthritis Rheumatol：新型JAK3/TEC抑制剂PF-06651600（ritlecitinib）对中重度类风湿性关节炎的疗效和安全性, objectType=article, longId=194372, objectId=d9c31943e212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c31943e212, replyNumber=0, likeNumber=14, createdTime=2021-01-04, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c31943e212, moduleTitle=Arthritis Rheumatol：新型JAK3/TEC抑制剂PF-06651600（ritlecitinib）对中重度类风湿性关节炎的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9c31943e212)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720945, encodeId=dd4b1e2094533, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet oncol：派姆单抗治疗未治疗过的脑转移的非小细胞肺癌的疗效和安全性, objectType=article, longId=191571, objectId=06631915e177, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06631915e177, replyNumber=0, likeNumber=74, createdTime=2021-02-17, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06631915e177, moduleTitle=Lancet oncol：派姆单抗治疗未治疗过的脑转移的非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06631915e177)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720923, encodeId=346e1e2092389, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Blood：达雷木单抗治疗AL淀粉样变的疗效和安全性, objectType=article, longId=187137, objectId=3fb318e137da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fb318e137da, replyNumber=0, likeNumber=51, createdTime=2020-07-01, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fb318e137da, moduleTitle=Blood：达雷木单抗治疗AL淀粉样变的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fb318e137da)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效和安全性

2020-05-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Blood：口服cedazuridine/地西他滨治疗MDS和CMML的药代动力学、疗效和安全性

2021-01-14

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet oncol：R-CHOP联合甲氨蝶呤和鞘内化疗治疗新确诊的IVLBCL的疗效和安全性

2020-10-09

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Arthritis Rheumatol：卡那单抗对sJIA患者的疗效和安全性

2021-06-04

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Blood：Ivosidenib 单药治疗新确诊的AML的疗效和安全性

2020-05-03

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Arthritis Rheumatol：乌司奴单抗治疗系统性红斑狼疮的1年疗效和安全性

2020-07-07

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Rheum Dis：两项使用ixekizumab治疗活动性放射学axSpA 3期临床试验的疗效和安全性（COAST-V和COAST-W）

2020-08-14

hb2008ye (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet oncol：维奈托克联合阿糖胞苷±伊达比星用于AML患儿的疗效和安全性

2021-01-21

hb2008ye (审核中...)

前往app查看评论内容

#疗效和安全性#

Medicine ：舍曲林治疗早泄的疗效和安全性分析

2020-12-26

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Stroke：大血管闭塞的急性缺血性卒中患者再通疗法的疗效和安全性

2020-06-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Blood：Avadomide(CC-122)单药治疗难治性/复发性DLBCL的疗效和安全性

2020-02-26

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Diabetes Obes Metab：老年2型糖尿病患者埃格列净治疗的疗效和安全性

2021-02-04

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

拜耳的Eylea在针对湿性年龄相关性黄斑变性的ALTAIR IV期研究中展现出疗效和安全性

2020-07-01

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Neurology：Eptinezumab单抗治疗慢性偏头痛的疗效和安全性

2020-06-11

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Urol Int：他达拉非每日一次与按需使用对勃起功能障碍患者的疗效和安全性

2020-08-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Gastroenterology：急诊和选择性结肠镜检查对急性下消化道出血的疗效和安全性分析

2020-09-24

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Rheum Dis：苏金单抗对难治性白塞病黏膜和关节表型的长期疗效和安全性

2021-04-03

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Clin Oncol：鲁索替尼治疗有无CSF3R突变的CNL或aCML患者的疗效和安全性

2020-03-06

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Arthritis Rheumatol：新型JAK3/TEC抑制剂PF-06651600（ritlecitinib）对中重度类风湿性关节炎的疗效和安全性

2021-01-04

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet oncol：派姆单抗治疗未治疗过的脑转移的非小细胞肺癌的疗效和安全性

2021-02-17

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Blood：达雷木单抗治疗AL淀粉样变的疗效和安全性

2020-07-01

科室
- - 订阅+
  - 更多科室
工具
服务